Equities

Cassava Sciences Inc

Cassava Sciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)27.23
  • Today's Change-4.95 / -15.38%
  • Shares traded4.94m
  • 1 Year change+27.96%
  • Beta-0.5600
Data delayed at least 15 minutes, as of Nov 22 2024 18:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.

  • Revenue in USD (TTM)0.00
  • Net income in USD-17.66m
  • Incorporated1998
  • Employees29.00
  • Location
    Cassava Sciences Inc6801 N. Capital of Texas HighwayBuilding 1AUSTIN 78731United StatesUSA
  • Phone+1 (512) 501-2444
  • Fax+1 (512) 614-0414
  • Websitehttps://www.cassavasciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Spyre Therapeutics Inc0.00-214.90m1.39bn60.00--8.09-----7.44-7.440.006.370.00----0.00-68.40-101.87-81.72-118.83-------2,949.59----0.00---61.96-25.61-304.21------
Bicycle Therapeutics PLC (ADR)36.90m-166.28m1.40bn284.00--1.68--37.91-3.28-3.280.716312.040.0451--0.9806129,922.50-20.33-29.45-22.03-32.98-----450.64-571.36----0.0002--86.5230.47-60.28--19.82--
Intellia Therapeutics Inc43.09m-522.28m1.40bn526.00--1.46--32.53-5.45-5.450.45099.460.0357--5.6281,912.55-43.22-31.34-47.07-34.53-----1,212.19-654.71----0.00---30.403.57-1.48--17.08--
Cassava Sciences Inc0.00-17.66m1.54bn29.00--9.26-----0.3772-0.37720.003.470.00----0.00-8.91-30.74-10.98-32.12------------0.00-------27.50------
Neumora Therapeutics Inc0.00-293.70m1.55bn108.00--4.85-----1.77-1.770.002.000.00----0.00-65.46---70.23--------------0.00-------80.23------
BioCryst Pharmaceuticals Inc412.58m-123.82m1.55bn536.00------3.76-0.6073-0.60732.01-2.260.81360.42976.54769,736.90-24.42-47.95-32.17-64.8998.0697.06-30.01-114.942.73-0.4882.29--22.3774.218.33--42.73--
Viridian Therapeutics Inc302.00k-257.08m1.55bn96.00--3.00--5,146.21-4.31-4.310.0058.940.0006--5.213,212.77-46.71-55.59-49.63-60.32-----85,127.15-5,678.12----0.0282---82.28-48.16-83.05--15.08--
Travere Therapeutics Inc203.45m-348.96m1.57bn380.00------7.69-4.52-4.562.63-0.39090.30430.719210.24535,386.80-52.19-36.95-69.25-44.7795.2195.92-171.52-165.791.68--1.09--32.69-2.43-13.54--16.49--
Nurix Therapeutics Inc56.42m-176.98m1.58bn284.00--3.98--28.08-2.91-2.910.92225.620.1373----198,676.10-43.07-33.01-52.51-39.66-----313.65-260.65----0.00--99.3115.5020.19--39.42--
Dynavax Technologies Corp260.81m20.48m1.62bn408.00101.252.3864.906.230.12210.12211.835.190.25630.804.36639,242.602.014.162.145.7182.8564.837.859.1912.34--0.2470.00-67.8695.19-102.18---23.03--
Recursion Pharmaceuticals Inc65.18m-377.75m1.65bn500.00--3.13--25.29-1.53-1.530.26311.830.096--24.06130,368.00-55.66---65.45--35.07---579.51------0.0519--11.88---36.99------
Xencor Inc85.16m-198.24m1.69bn280.00--2.33--19.80-3.20-3.201.3710.350.0967--2.61304,157.20-22.89-3.70-24.90-4.12-----236.81-15.92----0.0243--2.2832.90-128.50--18.36--
Structure Therapeutics Inc (ADR)0.00-110.55m1.72bn148.00--1.92-----2.21-2.210.0015.660.00----0.00-19.23---20.17--------------0.00-------69.62------
Arvinas Inc161.10m-308.60m1.73bn445.00--2.94--10.71-4.79-4.792.388.530.1448--14.01362,022.50-27.73-22.01-37.81-26.47-----191.56-316.55----0.001---40.2640.53-30.02--0.4852--
Data as of Nov 22 2024. Currency figures normalised to Cassava Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

20.68%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20242.94m6.13%
The Vanguard Group, Inc.as of 30 Sep 20242.40m5.01%
SSgA Funds Management, Inc.as of 30 Sep 20241.16m2.42%
Geode Capital Management LLCas of 30 Sep 20241.01m2.10%
Gallacher Capital Management LLCas of 30 Sep 2024580.04k1.21%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024393.19k0.82%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024389.27k0.81%
Tidal Investments LLCas of 30 Sep 2024375.00k0.78%
Charles Schwab Investment Management, Inc.as of 30 Sep 2024361.80k0.75%
Invesco Capital Management LLCas of 30 Sep 2024305.03k0.64%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.